Canopy Growth Earnings Reports

Canopy Growth posted a Q2 2026 net loss of $1.6M, significantly improved from the prior year. Revenue rose to $66.7M driven by strong growth in Canadian adult-use and medical cannabis. Gross margin remained steady, and operating losses shrank due to disciplined cost controls and lower SG&A expenses.

The company delivered strong cannabis revenue growth, led by a 43% increase in Canada adult-use sales, while Storz & Bickel revenues fell 25%. Gross margin declined to 25% due to product mix and lower high-margin market sales. Operating loss improved on reduced expenses. Adjusted EBITDA loss widened, but free cash flow outflow was significantly reduced.

Canopy Growth faced an 11% revenue decline in Q4 2025 compared to the same period last year, primarily due to weaker international and Storz & Bickel sales. Despite this, the company made progress in reducing operating losses and continues executing on cost-saving strategies.